Access Patient Co-Pay Assistance

^¶For patients to be eligible for the IV Co-Pay Program, they must have commercial insurance that covers BESPONSA™ (inotuzumab ozogamicin) or MYLOTARG™ (gemtuzumab ozogamicin) (each referred to as “Product”) and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the IV Co-Pay Program benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for Product administered in the outpatient setting.

^#The IV Co-Pay Program will pay the co-pay and any deductible obligations for the Product up to the annual assistance limit of $25,000 per calendar year per patient.

^**The IV Co-Pay Program provides assistance for eligible, commercially insured patients for co-pays, co-insurance, or deductibles incurred for the Product, up to $25,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with Product treatment.

^#For patients to be eligible for the Injectables Co-Pay Program for ZIRABEV, they must have commercial insurance that covers ZIRABEV™ (bevacizumab-bvzr) and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for ZIRABEV benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for ZIRABEV administered in the outpatient setting.

**The Injectables Co-Pay Program for ZIRABEV will pay the co-pays for ZIRABEV up to the annual assistance limit of $25,000 per calendar year per patient.

^††The Injectables Co-Pay Program for ZIRABEV provides assistance for eligible, commercially insured patients for co-pays or coinsurance incurred for ZIRABEV, up to $25,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with ZIRABEV treatment.

^#For patients to be eligible for the Injectables Co-Pay Program for RUXIENCE, they must have commercial insurance that covers RUXIENCE™ (rituximab-pvvr) and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for RUXIENCE benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for RUXIENCE administered in the outpatient setting.

**The Injectables Co-Pay Program for RUXIENCE will pay the co-pays for RUXIENCE up to the annual assistance limit of $25,000 per calendar year per patient.

^††The Injectables Co-Pay Program for RUXIENCE provides assistance for eligible, commercially insured patients for co-pays or coinsurance incurred for RUXIENCE, up to $25,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with RUXIENCE treatment.

^#For patients to be eligible for the Injectables Co-Pay Program for TRAZIMERA, they must have commercial insurance that covers TRAZIMERA™ (trastuzumab-qyyp) and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for TRAZIMERA benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for TRAZIMERA administered in the outpatient setting.

**The Injectables Co-Pay Program for TRAZIMERA will pay the co-pays for TRAZIMERA up to the annual assistance limit of $25,000 per calendar year per patient.

^††The Injectables Co-Pay Program for TRAZIMERA provides assistance for eligible, commercially insured patients for co-pays or coinsurance incurred for TRAZIMERA, up to $25,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with TRAZIMERA treatment.

^#For patients to be eligible for the Injectables Co-Pay Program, they must have commercial insurance that covers ZIRABEV™ (bevacizumab-bvzr) (referred to as “Product”) and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for Product administered in the outpatient setting.

^**The Injectables Co-Pay Program will pay the co-pay and any deductible obligations for the Product up to the annual assistance limit of $25,000 per calendar year per patient.

^††The Injectables Co-Pay Program provides assistance for eligible, commercially insured patients for co-pays, coinsurance, or deductibles incurred for the Product, up to $25,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with Product treatment.

^#For patients to be eligible for the Injectables Co-Pay Program for NIVESTYM, they must have commercial insurance that covers NIVESTYM^® (filgrastim-aafi) and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for NIVESTYM benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for NIVESTYM administered in the outpatient setting.

**The Injectables Co-Pay Program for NIVESTYM will pay the co-pays for NIVESTYM up to the annual assistance limit of $10,000 per calendar year per patient.

^††The Injectables Co-Pay Program for NIVESTYM provides assistance for eligible, commercially insured patients for co-pays or coinsurance incurred for NIVESTYM, up to $10,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with NIVESTYM treatment.